• Developmental SSRI Exposure and Motivation Deficits

  2026-08-21

  A 2026 Columbia dissertation found that developmental SSRI exposure selectively impaired effortful reward seeking in adolescent and adult mice, while reward licking and Pavlovian learning were comparatively preserved. Pharmacological antagonism or nucleus accumbens knockdown of mu opioid receptors attenuated the motivational phenotype, pointing to opioid-reward circuitry as a mechanistic target distinct from repeated SSRI treatment.

• VX-765: Reading Caspase-1 Assays Correctly

  2026-08-20

  VX-765 and its active metabolite VRT-043198 are valuable tools for dissecting caspase-1 signaling, but recent evidence reveals important assay-context limitations. This guide connects inflammasome biology with practical controls for cytokine, pyroptosis, and cross-caspase experiments.

• Chlorpromazine HCl in Mechanism-First Assays

  2026-08-20

  Chlorpromazine HCl is more than a conventional dopamine receptor antagonist: it can serve as a calibrated pharmacological perturbation across receptor, synaptic, and cell-based experiments. This guide connects its neuropharmacology to a recent electrical-stimulation study of nanoparticle endocytosis while clearly separating established evidence from assay hypotheses.

• Doxorubicin Hydrochloride: A Dual-Assay Framework

  2026-08-19

  Doxorubicin hydrochloride can be used to build a matched experimental framework that measures tumor-cell injury alongside cardiac stress. This article translates mechanistic evidence on ferroptosis, oxidative injury, and Nrf2/HO-1 signaling into practical assay decisions for cancer chemotherapy research.

• Rottlerin PKC Inhibitor: Assay Workflows

  2026-08-19

  Use Rottlerin as a PKC inhibitor to connect signaling perturbation with cell proliferation inhibition, apoptosis induction, and mechanistic uptake assays. This guide adapts an ocular nanoparticle workflow into a controlled PKC-dependence experiment while emphasizing viability controls, pathway-specific readouts, and reproducibility.

• CPI-613: Mechanism and Cancer Research Use

  2026-08-18

  CPI-613, also known as 6,8-bis(benzylsulfanyl)octanoic acid, is a lipoate-derived mitochondrial metabolism inhibitor for cancer research. Its reported PDH and KGDH activity provides a rationale for apoptosis assays, tumor cell metabolism studies, and chemotherapy-combination experiments, but preclinical findings should not be interpreted as clinical efficacy.

• Acifran Workflows for GPCR Lipid Signaling

  2026-08-18

  Acifran enables controlled activation studies of HM74A/GPR109A and GPR109B/HCAR3 in cell-based and structure-guided research. This practical guide combines assay setup, concentration planning, receptor comparison, and troubleshooting for lipid metabolism and signaling applications.

• Phosphatase Inhibitor Cocktail 2: Use & Limits

  2026-08-17

  Phosphatase Inhibitor Cocktail 2 is a 100X aqueous reagent for broad phosphatase suppression during sample preparation. Its defined dilution and storage specifications support protein phosphorylation preservation, but assay-specific compatibility and phosphatase coverage still require validation.

• Triamcinolone: Practical Research Protocol Guide

  2026-08-17

  Triamcinolone (SKU B1859) provides a defined synthetic glucocorticoid agonist input for in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. Its water and ethanol insolubility, DMSO solubility, solid-state storage requirement, and research-only status must be addressed before use; it is not intended for diagnostic, therapeutic, or clinical applications.

• 4-Ethylphenyl Sulfate: Assay Design

  2026-08-16

  4-Ethylphenyl sulfate is a microbiota-derived metabolite linking renal and neurobehavioral research. This guide introduces a matrix-aware strategy for interpreting biomarker, mouse-model, and blood-contacting material assays.

• Troglitazone: PPARγ Agonist Workflows

  2026-08-15

  Troglitazone gives researchers a practical way to connect PPARγ/α signaling with lipid and glucose metabolism, macrophage state, and exploratory renal carcinoma assays. This guide translates the SPP1-focused tumor-myeloid study into controlled, product-specific workflows without overstating what the reference directly tested.

• Abiraterone Acetate in 3D Prostate Models

  2026-08-15

  Abiraterone acetate is a CYP17 inhibitor that can reveal how androgen biosynthesis shapes prostate tumor biology. This evidence-led guide explains why patient-derived 3D spheroids may show weak viability responses, and how to pair pathway and structural readouts for more informative prostate cancer research.

• TAI-1 Hec1 Inhibitor Workflow Guide

  2026-08-14

  TAI-1 enables mechanism-led studies of Hec1–Nek2 disruption, mitotic failure, and apoptotic cell death induction across cancer models. This guide connects dose-response, combination, and retinal organoid workflows while distinguishing reported product performance from practical assay starting points.

• Rucaparib Workflows for DNA Repair Research

  2026-08-14

  Build reproducible Rucaparib experiments for PARP biology, irradiation studies, and spliceosome-linked drug sensitivity. This guide combines practical treatment matrices, damage-response readouts, and troubleshooting for models ranging from hepatocellular carcinoma to prostate cancer.

• DOTAP and the Next Wave of Translational Delivery

  2026-08-13

  1,2-Dioleoyl-3-trimethylammonium-propane chloride, or DOTAP, provides a practical bridge between controlled nucleic acid delivery and emerging immune-metabolic research. This thought-leadership analysis explains the delivery mechanism, validation strategy, translational limits, and opportunities for lipid nanoparticle optimization inspired by recent Nano-ZD findings.

449 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page